Tag: BIT
Biotron ruffles through its compound database in search of COVID-19 drug
The chase for effective COVID-19 treatments is well and truly on after biotech company Biotron (ASX: BIT) confirmed it intends to harness its proprietary compounds to develop a treatment for SARS-CoV-...
Biotron’s BIT225 drug show to enhance body’s immune response to HIV
Biotron’s (ASX: BIT) lead candidate HIV-1 drug BIT225 has been shown to boost the body’s immune response to HIV by inhibiting viral protein Vpu, while also having an anti-viral effect.
The company ...
Biotron presents further phase 2 trial results for HIV drug BIT225
Clinical stage company Biotron (ASX: BIT) is preparing to present results from its ongoing phase 2 trial into its lead BIT225 drug at the annual Conference on Retroviral and Opportunistic Infections (...
Biotron to commence testing of compounds to destroy coronavirus
Australian clinical stage company Biotron (ASX: BIT) has announced it will commence the evaluation of “several promising compounds” which could target various strains of coronavirus, including the dea...
Biotron rides wave of Phase 2 clinical trial success for HIV drug
Biotechnology company Biotron (ASX: BIT) is enjoying its moment in the sun on the back of a skyrocketing share price since news of a successful Phase 2 clinical trial for its BIT225 HIV drug hit the m...
